HotSpot IRF5 Inhibitor Hits Three Lupus Pathways in Preclinical Data
Image
Boston – November 10, 2026 -- HotSpot Therapeutics reported preclinical data showing that its oral IRF5 inhibitor HST-2011 suppressed three disease-driving pathways in systemic lupus erythematosus (SLE) across human cell systems, human whole blood and cynomolgus monkeys. The data were presented in a poster at ACR Convergence 2026.
HST-2011 reduces B cell, interferon and cytokine readouts in three models
In human cellular systems, HST-2011 inhibited plasmablast formation and IgG production. It also potently inhibited type I interferon and proinflammatory cytokine production, including TNF and IL-1β.
In human whole blood stimulated with a TLR agonist, the compound reduced plasmablast, B-cell activation and interferon gene signature scores. mRNA sequencing showed reduced expression of IFNB1, TNF and IL1B.